Arcturus Therapeutics Holdings Inc. (ARCT)
ARCTNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$9.49
-0.1100 (-1.15%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $273.53m
- P/E
- –
- EPS, last 4 quarters
- $-3.08
- Dividend yield
- –
- Day range
- –
- 52-week range
- $5.50 to $17.96
- Average volume
- 800.8k
- Previous close
- $9.60
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $21.38, +125.3% from here
Earnings
next estimate $-1.01Next report
Dec 2025
-12.0%
Mar 2026
+16.7%
Jun 2026
+21.5%
Sep 2026
+56.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $17.15m | $7.20m | $2.06m | $2.96m |
| Gross profit | $17.15m | $7.20m | $2.06m | $2.96m |
| Operating income | -$16.51m | -$31.31m | -$28.93m | -$25.55m |
| Net income | -$13.45m | -$29.08m | -$26.96m | -$23.79m |
Last four quarters: revenue $29.37m, margin -317.6%, free cash flow –
News
8 latest- Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline ProgressFintel · 4 days ago
- Arcturus (ARCT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings CallMarketBeat · 4 days ago
- Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue EstimatesZacks · 4 days ago
- Ocugen (OCGN) Reports Q3 Loss, Tops Revenue EstimatesZacks · 6 days ago
- Are Medical Stocks Lagging Agilon Health (AGL) This Year?Zacks · Oct 23, 2026
- Arcutis Partners With Simone Biles To Raise Awareness Of Skin Conditions RTTNews · Sep 29, 2026
- 4 RNA Therapeutics Stocks Leading the Next Wave of InnovationZacks · Sep 28, 2026
The company
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory therapeutics with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus' strategic collaborations include Thermo Fisher Scientific for ARCT-032 manufacturing and development, BARDA for pandemic influenza initiatives, and ARCALIS, a Japanese joint venture focused on manufacturing mRNA vaccines and therapeutics. Arcturus' pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Middle East
- Website
- arcturusrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.